Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes

被引：40

作者：

Bar-Magen, Tamara ^{[1
]}

Sloan, Richard D. ^{[1
]}

Faltenbacher, Verena H. ^{[1
]}

Donahue, Daniel A. ^{[1
,2
]}

Kuhl, Bjoern D. ^{[1
,3
]}

Oliveira, Maureen ^{[1
]}

Xu, Hongtao ^{[1
]}

Wainberg, Mark A. ^{[1
,2
,3
]}

机构：

[1] McGill Univ, AIDS Ctr, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada

[2] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2T5, Canada

[3] McGill Univ, Div Expt Med, Montreal, PQ H3A 2T5, Canada

来源：

RETROVIROLOGY | 2009年 / 6卷

基金：

加拿大健康研究院;

关键词：

DNA INTEGRATION; STRAND-TRANSFER; IN-VITRO; VIRUS; RESISTANCE; RALTEGRAVIR; PROTEIN; INHIBITORS; MUTATIONS; ELVITEGRAVIR;

D O I：

10.1186/1742-4690-6-103

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Background: Integrase inhibitors are currently being incorporated into highly active antiretroviral therapy (HAART). Due to high HIV variability, integrase inhibitor efficacy must be evaluated against a range of integrase enzymes from different subtypes. Methods: This study compares the enzymatic activities of HIV-1 integrase from subtypes B and C as well as susceptibility to various integrase inhibitors in vitro. The catalytic activities of both enzymes were analyzed in regard to each of 3' processing and strand transfer activities both in the presence and absence of the integrase inhibitors raltegravir (RAL), elvitegravir (EVG), and MK-2048. Results: Our results show that integrase function is similar with enzymes of either subtype and that the various integrase strand transfer inhibitors (INSTIs) that were employed possessed similar inhibitory activity against both enzymes. Conclusion: This suggests that the use of integrase inhibitors against HIV-1 subtype C will result in comparable outcomes to those obtained against subtype B infections.

引用

页数：10

共 32 条

[11] HIV-1 DNA INTEGRATION - MECHANISM OF VIRAL-DNA CLEAVAGE AND DNA STRAND TRANSFER [J].

ENGELMAN, A ;

MIZUUCHI, K ;

CRAIGIE, R .

CELL, 1991, 67 (06) :1211-1221

[12] Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial [J].

Grinsztejn, Beatriz ;

Nguyen, Bach-Yen ;

Katlama, Christine ;

Gatell, Jose M. ;

Lazzarin, Adriano ;

Vittecoq, Daniel ;

Gonzalez, Charles J. ;

Chen, Joshua ;

Harvey, Charlotte M. ;

Isaacs, Robin D. .

LANCET, 2007, 369 (9569) :1261-1269

[13] Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes [J].

Grobler, JA ;

Stillmock, K ;

Hu, BH ;

Witmer, M ;

Felock, P ;

Espeseth, AS ;

Wolfe, A ;

Egbertson, M ;

Bourgeois, M ;

Melamed, J ;

Wai, JS ;

Young, S ;

Vacca, J ;

Hazuda, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (10) :6661-6666

[14] A NOVEL ASSAY FOR THE DNA STRAND-TRANSFER REACTION OF HIV-1 INTEGRASE [J].

HAZUDA, DJ ;

HASTINGS, JC ;

WOLFE, AL ;

EMINI, EA .

NUCLEIC ACIDS RESEARCH, 1994, 22 (06) :1121-1122

[15] A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase [J].

Hazuda, DJ ;

Anthony, NJ ;

Gomez, RP ;

Jolly, SM ;

Wai, JS ;

Zhuang, LH ;

Fisher, TE ;

Embrey, M ;

Guare, JP ;

Egbertson, MS ;

Vacca, JP ;

Huff, JR ;

Felock, PJ ;

Witmer, MV ;

Stillmock, KA ;

Danovich, R ;

Grobler, J ;

Miller, MD ;

Espeseth, AS ;

Jin, LX ;

Chen, IW ;

Lin, JH ;

Kassahun, K ;

Ellis, JD ;

Wong, BK ;

Xu, W ;

Pearson, PG ;

Schleif, WA ;

Cortese, R ;

Emini, E ;

Summa, V ;

Holloway, MK ;

Young, SD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (31) :11233-11238

[16] Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells [J].

Hazuda, DJ ;

Felock, P ;

Witmer, M ;

Wolfe, A ;

Stillmock, K ;

Grobler, JA ;

Espeseth, A ;

Gabryelski, L ;

Schleif, W ;

Blau, C ;

Miller, MD .

SCIENCE, 2000, 287 (5453) :646-650

[17] A soluble active mutant of HIV-1 integrase - Involvement of both the core and carboxyl-terminal domains in multimerization [J].

Jenkins, TM ;

Engelman, A ;

Ghirlando, R ;

Craigie, R .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (13) :7712-7718

[18] Implications of HIV-1 M Group Polymorphisms on Integrase Inhibitor Efficacy and Resistance: Genetic and Structural in Silico Analyses [J].

Loizidou, Eriketi Z. ;

Kousiappa, Ioanna ;

Zeinalipour-Yazdi, Constantinos D. ;

Van de Vijver, David A. M. C. ;

Kostrikis, Leondios G. .

BIOCHEMISTRY, 2009, 48 (01) :4-6

[19] Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases [J].

Malet, Isabelle ;

Soulie, Cathia ;

Tchertanov, Luba ;

Derache, Anne ;

Amellal, Bahia ;

Traore, Ousmane ;

Simon, Anne ;

Katlama, Christine ;

Mouscadet, Jean-Frangois ;

Calvez, Vincent ;

Marcelin, Anne-Genevieve .

JOURNAL OF MEDICAL VIROLOGY, 2008, 80 (05) :754-761

[20] Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro [J].

Malet, Isabelle ;

Delelis, Olivier ;

Valantin, Marc-Antoine ;

Montes, Brigitte ;

Soulie, Cathia ;

Wirden, Marc ;

Tchertanov, Luba ;

Peytavin, Gilles ;

Reynes, Jacques ;

Mouscadet, Jean-Francois ;

Katlama, Christine ;

Calvez, Vincent ;

Marcelin, Anne-Genevieve .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) :1351-1358

← 1 2 3 4 →